Comparative Pharmacology
Head-to-head clinical analysis: CLOBAZAM versus DORAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOBAZAM versus DORAL.
CLOBAZAM vs DORAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clobazam is a benzodiazepine that enhances the effect of GABA at the GABA-A receptor, increasing chloride ion conductance and neuronal hyperpolarization. It has a high affinity for the α2 subunit, which may contribute to its anticonvulsant effects.
GABAA receptor positive allosteric modulator; enhances the inhibitory effects of GABA by binding to benzodiazepine receptors, increasing chloride channel opening frequency.
10-60 mg orally once daily, divided into two doses. Typical starting dose: 10 mg twice daily.
15-30 mg orally at bedtime, maximum 60 mg/day.
None Documented
None Documented
Clobazam: 36–42 hours; N-desmethylclobazam: 71–82 hours. Steady state achieved in 5–10 days.
Clinical Note
moderateClobazam + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Clobazam."
Clinical Note
moderateClobazam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Clobazam is combined with Fluticasone propionate."
Clinical Note
moderateClobazam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Clobazam."
Clinical Note
moderateClobazam + Erythromycin
Terminal elimination half-life: 40-120 hours (long-acting benzodiazepine). Accumulation occurs with repeated dosing, especially in elderly or hepatic impairment.
Renal: ~82% as metabolites (mainly N-desmethylclobazam and hydroxylated metabolites), unchanged clobazam <1%; fecal: ~11%.
Renal (primarily as metabolites; <1% unchanged). Biliary/fecal: minor.
Category C
Category C
Benzodiazepine
Benzodiazepine
"The metabolism of Erythromycin can be decreased when combined with Clobazam."